About QurieGen
Our Mission
Our Mission
Advancing drug development with cutting-edge single-cell technologies and predictive disease biology to accelerate the creation of life-changing treatments.
Our Vision
Our Vision
Unlocking the full potential of digital biology to ensure every patient has access to breakthrough treatments and precision medicine.
OUR HISTORY
QurieGen is a dutch spin-off from Radboud University estalished to accelerate and de-risk drug development through a faster, more affordable, and more data-driven approach. Our platform-based approach combines proprietary technology for cellular mapping, single-cell genomics, and advanced data science to build predictive disease biology and drug response models, reducing risks and accelerating drug discovery. QuRIE-seq was developed by the Huck group at Radboud University, leveraging our leading expertise in lab-on-chip and single-cell technologies, molecular biology, and bioinformatics. Before QurieGen’s official launch, our team pioneered single-cell technologies, especially utilizing droplet microfluidics, publishing extensively and filing patents. Today, we continue to further develop our QuRIE-seq and next platforms, providing deep insights into understanding disease mechanisms and MoA, enabling more informed decision-making throughout the drug development process.
TRUSTED BY LEADING COMPANIES
Meet Our Team
Our fast-growing team is a dynamic mix of life scientists, computational and technical experts, pharma professionals, clinicians, drug hunters, and business and operational leaders. We cultivate an environment where unique data, computational power, and creative thinking come together to solve complex challenges.
Dr. eng. Kinga Matula
ceo & co-founder
Kinga is a biotechnologist, PhD in physical chemistry, and VC analyst with 15+ years of research experience at the intersection of chemistry, biotechnology, and genetics. She conducted research at leading institutions in Europe, including the Max Planck Institute, and received business training in Europe and the U.S. (Silicon Valley, Los Angeles), securing 10 startup awards for QurieGen.
During her postdoctoral fellowship, she specialized in developing single-cell analysis platforms. As a former oncology patient, she is deeply committed to bridging innovation and patient care. Transitioning from academia to biotech, she co-founded QurieGen and co-developed QuRIE-seq, the company’s flagship platform, designed to address pharmaceutical industry needs.
She studied at the Otto-von-Guericke University Magdeburg and worked at the Max Planck Institute for Dynamic and Complex Technical Systems in Magdeburg (Germany) where she prepared her master thesis in chemical and process engineering. Afterward, she started her Ph.D. in soft condensed matter at the Institute of Physical Chemistry of the Polish Academy of Sciences in Warsaw (Poland). In 2018, Kinga joined the group of Professor Wilhelm Huck where she was working on development of droplet microfluidic platforms for single-cell analysis.
After 15 years of interdisciplinary research, Kinga transitioned from academia to the biotech industry to ensure that scientific discoveries could have an immediate and tangible impact. From the outset, she has been building QurieGen and co-developing QuRIE-seq, their flagship platform, created in response to demand from the pharmaceutical industry. Under Kinga’s leadership, QurieGen has achieved significant milestones, including winning the Venture Challenge (May 2022), securing a Golden Ticket to Silicon Valley’s prestigious accelerator (July 2022), and earning top placements in global competitions such as the XTC Winner in 2024. With business training across Europe and the U.S., coupled with experience as a VC analyst, Kinga brings a global perspective to biotech entrepreneurship. However, her passion for biological discoveries, particularly in single-cell research and systems biology, remains her driving force.
Her commitment to QurieGen’s mission is deeply personal. Growing up, she was inspired by her mother’s work in a hospital, which ignited her desire to help patients. In 2018, her perspective on healthcare changed dramatically when she became an oncology patient. For her, the mission to improve patient care and her passion for science are not just professional pursuits—they are deeply personal, and they inspire everything she does.
Maciej Jarzab
COO & co-founder
Maciej is a serial entrepreneur, VC, and business angel with experience in consulting, banking, and venture capital. He began his career at McKinsey & Company, where he honed his problem-solving and structured thinking skills. At mBank S.A., he refined investment banking techniques.
Driven to address challenges in finance through technology, Maciej co-founded Braight, an AI-powered company revolutionizing credit scoring for young and unbanked individuals. Braight’s innovative solution using behavioral analysis based on online data gained significant market traction and was eventually acquired by a Canadian firm listed on the Toronto Stock Exchange.
As a natural leader and curious thinker, Maciej’s drive to address major issues in the finance industry through technology led him to co-found Braight, an AI-powered company transforming credit scoring for young and unbanked individuals. Recognizing the outdated nature of traditional credit scoring systems,, Maciej and his team developed a novel credit scoring enrichment solution using behavioral analysis based on online user data. This innovative approach aimed not only to assist young people but also to serve a broader audience, including unbanked populations in less economically developed countries.
Under Maciej’s leadership, Braight expanded its operations across multiple industries and gained significant market traction. The company was later acquired by a Canadian firm listed on the Toronto Stock Exchange, underscoring the success and impact of Maciej’s vision and execution in the fintech space.
